Company intelligence / Profile preview
Bluejay Therapeutics
San Mateo/Redwood City, California, United Statesbluejaytx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Brelovitug (BJT-778) achieved 100% virologic response across all dose arms and up to 78% combined virologic response and ALT normalization as a monotherapy in Phase 2 trials for CHD. The drug received FDA Breakthrough Therapy designation in January 2025 and has PRIME and Orphan designations from the European Medicines Agency. The first patient was dosed in the AZURE-1 global pivotal clinical trial in March 2025.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)TLR9 agonistHBV transcript inhibitor
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Licensing agreement with Novartis for BJT-628
Beyond the preview
Go deeper on Bluejay Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bluejay Therapeutics.